Stock screener
All disclosures →
EDGAR →
ALKS
Conviction 60HealthcareScan · Tue, Sep 8, 2026ALKS$45.49-1.33%
ResistanceSupportVol 14Insider sellCongress buyCongress sell2
Vol MA14 1.33M
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Price45.49
Change-1.33%
Gap-1.63%
Rel volume1.14×
Avg volume1.29M
Avg $ vol62.53M
SMA 2048.39
SMA 5050.38
SMA 20037.79
Price vs 50-9.71%
Price vs 200+20.36%
MA stackmixed
50/200 cross—
Supertrenddown · 50.04
RSI (14)34
MACD hist-0.29
MACD cross—
Stoch %K / %D10 / 8
ADX (14)21
+DI / −DI15 / 28
RSI divergence—
MACD divergence—
ATR %+3.34%
ADR %2.89%
52w high55.22
52w low26.52
From 52w high-17.63%
Above 52w low+71.51%
New 52w highNo
SqueezeOff
Bollinger width10.93%
%B-0.05
Donchian pos9.79%
Donchian high51.66
Donchian low44.82
AVWAP (52w high)50.19
vs AVWAP high-9.38%
AVWAP (52w low)35.69
vs AVWAP low+27.45%
OBV trendDown
Chaikin MF (20)-0.16
Today vs 20d1.14×
Avg vol (14d)1.33M
Avg vol (20d)1.29M
Avg $ vol (20d)62.53M
Market cap7.63B
RS 3m (vs SPY)+3.28%
RS 6m (vs SPY)+46.47%
RS line new highNo
Trend template7/8
Technical rank58.9
1 week-3.20%
1 month-7.49%
3 months+7.15%
6 months+59.88%
1 year+51.92%
YTD+60.95%
P/E31.58
P/B4.22
P/S5.17
P/FCF15.89
EPS1.43
Div yield—
ROE13.36%
ROA5.50%
Debt/Eq0.83
Current2.30
EV/EBITDA30.67
Gross margin—
Net margin16.37%
Rev growth-5.25%
EPS growth-34.16%
Price target58.25
Target upside28.06%
Analyst ratingBuy
Institutional121.79%
Ent. value8.62B
Revenue496.01M
Net income501K
Gross profit—
Free cash flow480.33M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out166.68M
Employees2.05K
ListedTue, Jul 16, 1991
Free float162.41M
Float %98.4%
Short interest14.76M
Days to cover10.2d
Short volume34.8%
Squeeze score45 / 100
Next earnings—
EPS forecast—
Last EPS vs est$0.00 vs −$0.04
Last surprise+100.0% beat
Setup gradeB
Conviction60 / 100
Pattern quality—
Tech rank58.9 / 100
Group rank96 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance53.70
Support46.90
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in ALKS · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
Gilbert Cisneros house · D · CA · traded 2026-07-30 | Buy | $15K–$50K | 2026-07-30 | 2026-09-04 |
Insider activity
SEC Form 4 transactions in ALKS · 3 buys · 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-09-01 | Sell | 9K | $423K | 2026-09-01 | 2026-09-01 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-09-01 | Exercise | 5K | $123K | 2026-09-01 | 2026-09-01 |
Hopkinson Craig C. EVP R&D, Chief Medical Officer · Employee Stock Option (Right to Buy) · 2026-09-01 | Exercise | 5K | — | 2026-09-01 | 2026-09-01 |
Nichols Christian Todd SVP, Chief Commercial Officer · Ordinary Shares · 2026-08-17 | Sell | 6.91K | $340K | 2026-08-17 | 2026-08-17 |
Nichols Christian Todd SVP, Chief Commercial Officer · Ordinary Shares · 2026-08-17 | Sell | 664 | $33K | 2026-08-17 | 2026-08-17 |
Jackson Blair Curtis President & CEO, Alkermes plc · Employee Stock Option (Right to Buy) · 2026-08-05 | Grant | 93.23K | — | 2026-08-05 | 2026-08-07 |
Jackson Blair Curtis President & CEO, Alkermes plc · Employee Stock Option (Right to Buy) · 2026-08-05 | Grant | 124.31K | — | 2026-08-05 | 2026-08-07 |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-07-06 | Sell | 2.03K | $110K | 2026-07-06 | 2026-07-06 |
Wright Christopher I Director · Ordinary Shares · 2026-06-12 | Sell | 2K | $90K | 2026-06-12 | 2026-06-12 |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-06-04 | Sell | 2.03K | $88K | 2026-06-04 | 2026-06-04 |
SEC filings
EDGAR filings in ALKS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.